Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

BBH vs. BIB: which is better?

Bottom line

BBH vs BIB: the short answer

BBH (VanEck Biotech ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 48% by weight.

But BIB is far broader, holding 267 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.

BBH is cheaper at 0.35% vs 0.95% — a difference of $60 a year per $10,000 invested.

Over five years, BBH returned +2.7% a year vs −1.0% for BIB.

Updated Nov 19, 2026

BBH vs BIB side by side

BBHBIB
TypeETFETF
Fund familyVanEckProShares
CategoryTechnology SectorTechnology Sector
Expense ratio0.35%0.95%
Annual cost per $10k$35$95
10-yr cost on $10k (prospectus)$443$1,401
Max front loadNoneNone
12b-1 fee——
1-yr return+21.2%+59.3%
5-yr return (annualized)+2.7%−1.0%
10-yr return (annualized)+4.5%+1.4%
Best quarter+27.6%+56.2%
Worst quarter−18.2%−42.7%
Net assets (fund)$395.6M$73.7M
Number of holdings25267
Portfolio turnover19%29%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearBBHBIBDifference
2025+21.2%+59.3%−38.2%
2024−4.4%−10.0%+5.6%
2023+3.9%−1.3%+5.1%
2022−15.1%−28.6%+13.5%
2021+11.8%−5.9%+17.7%
2020+22.1%+39.7%−17.7%
2019+25.8%+45.5%−19.8%
2018−10.2%−24.4%+14.2%
2017+16.6%+40.8%−24.1%
2016−15.0%−44.2%+29.2%

Source: Fund prospectus bar charts

Holdings overlap

13 of BBH's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingBBHBIB
Amgen Inc15.25%4.48%
Gilead Sciences Inc12.79%4.66%
Vertex Pharmaceuticals Inc9.10%4.65%
Regeneron Pharmaceuticals Inc6.21%3.21%
Revolution Medicines Inc5.27%1.57%
Argenx SE4.97%1.19%
Alnylam Pharmaceuticals Inc3.83%2.01%
Biogen Inc3.63%1.44%
Moderna Inc3.36%0.94%
Illumina Inc3.17%1.25%
United Therapeutics Corp2.83%1.22%
Insmed Inc2.67%1.16%
Incyte Corp2.49%0.97%

Source: SEC Form N-PORT

BBH top 10

  1. Amgen Inc — 15.25%
  2. Gilead Sciences Inc — 12.79%
  3. Vertex Pharmaceuticals Inc — 9.10%
  4. Regeneron Pharmaceuticals Inc — 6.21%
  5. Revolution Medicines Inc — 5.27%
  6. Argenx SE — 4.97%
  7. Natera Inc — 4.92%
  8. IQVIA Holdings Inc — 4.31%
  9. Alnylam Pharmaceuticals Inc — 3.83%
  10. Biogen Inc — 3.63%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between BBH and BIB?
BBH (VanEck Biotech ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 48% by weight. But BIB is far broader, holding 267 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
Which is cheaper, BBH or BIB?
BBH has the lower expense ratio (0.35%).
Should I own both BBH and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.